Most Socially Vulnerable Counties Less Likely to Have Cancer Trials
By Elana Gotkine HealthDay Reporter
TUESDAY, May 7, 2024 -- The most socially vulnerable counties are less likely to have any cancer clinical trial, according to a research letter published online May 7 in JAMA Network Open.
Rishi Robert Sekar, M.D., from the University of Michigan in Ann Arbor, and colleagues examined the association between county-level social determinants of health (SDOH) and cancer clinical trial availability in the United States. Cross-sectional and longitudinal analyses of county-level trial availability and SDOH were performed.
The study included 3,142 counties with a mean Social Vulnerability Index (SVI) of 0.50 and median population of 10,163 people. The researchers found that 58.4 percent of the counties included in the study had any trial during the study period, while the mean number of county-level population-adjusted trials was 342.1. The most socially vulnerable counties were less likely than the least socially vulnerable counties to have any trial in a multivariable analysis (49.6 versus 70.0 percent; odds ratio, 0.33), and they had fewer population-adjusted trials (223.4 versus 579.2; incidence rate ratio, 0.39). Throughout the study period, these observations were seen across SVI quintiles, with stable differences noted in the proportion of counties with any trial and a relative increase in the mean number of trials for the least socially vulnerable counties.
"This study emphasizes the role of SDOH in the disparate availability of cancer clinical trials and demonstrates the need to identify socially vulnerable communities for expansion of trial opportunities toward improving representation in studies and ensuring equitable cancer care," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Vaginal Cancer Incidence Increasing Globally
WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.